Patents by Inventor Ji-Wang Chern
Ji-Wang Chern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11535598Abstract: Histone deacetylases (HDACs) inhibitors are disclosed according to the following structural formula. The moiety A is a benzene ring, optionally substituted. The moiety B is a benzene ring attached at the 1,4 or 1,3 position, or a cyclohexane ring attached at the 1,4 position, optionally substituted. R and Z are further substituents. The HDACs inhibitors possess cytotoxicities to various cancer cell lines. They are useful for treating a tumor associated with deregulation of the activity of histone deacetylases in a subject in need thereof, in one embodiment, the HDACs inhibitors of the invention are useful for treating glioma, breast cancer, colon cancer, target cell lung cancer, adenocarcinoma of the lung, small cell lung cancer, stomach cancer, liver cancer, ovary adenocarcinoma, pancreas carcinoma, prostate carcinoma, promyiocytic leukemia, chronic myelocytic leukemia, or acute lymphocytic leukemia in a subject in need thereof.Type: GrantFiled: May 15, 2018Date of Patent: December 27, 2022Assignee: AnnJi Pharmaceutical Co., Ltd.Inventors: Ji-Wang Chern, Chao-Wu Yu, Jia-Rong Liu, Yi-Hsun Ho, Chia-Yu Wu, Chan-Hui Huang, Pei-Yun Hung
-
Publication number: 20210355089Abstract: Histone deacetylases (HDACs) inhibitors are disclosed. The HDACs inhibitors possess cytotoxicities to various cancer cell lines. They are useful for treating a tumor associated with deregulation of the activity of histone deacetylases in a subject in need thereof, in one embodiment, the HDACs inhibitors of the invention are useful for treating glioma, breast cancer, colon cancer, target cell lung cancer, adenocarcinoma of the lung, small cell lung cancer, stomach cancer, liver cancer, ovary adenocarcinoma, pancreas carcinoma, prostate carcinoma, promyiocytic leukemia, chronic myelocytic leukemia, or acute lymphocytic leukemia in a subject in need thereof.Type: ApplicationFiled: May 15, 2018Publication date: November 18, 2021Inventors: Ji-Wang CHERN, Chao-Wu YU, Jia-Rong LIU, Yi-Hsun HO, Chia-Yu WU, Chan-Hui HUANG, Pei-Yun HUNG
-
Patent number: 9387209Abstract: Histone deacetylases inhibitors (HDACIs) and compositions comprising the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit are also disclosed. In one aspect, the invention relates to a compound having the structure or a pharmaceutically acceptable salt, a solvate or hydrate, a prodrug, or a metabolite thereof. In one embodiment of the invention, R1 is ethyl; R2 is 2-phenylethyl; R3 is hydrogen; R4 is fluoro; R5 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; and R6 is hydrogen, or a salt thereof. In another embodiment of the invention, R1 is ethyl; R2 is 2-phenylethyl; R3 is hydrogen; R4 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; R5 is chloro or fluoro; and R6 is hydrogen, or a salt thereof.Type: GrantFiled: April 2, 2013Date of Patent: July 12, 2016Assignee: ANNJI PHARMACEUTICAL CO., LTD.Inventors: Ji-Wang Chern, Chao-Wu Yu, Pei-Teh Chang
-
Patent number: 9302992Abstract: Novel quinoline derivatives are disclosed. Also disclosed are synthesis and use thereof for treating neurodegenerative diseases.Type: GrantFiled: April 2, 2013Date of Patent: April 5, 2016Assignee: ANNJI PHARMACEUTICAL CO., LTD.Inventors: Ji-Wang Chern, Chen-Wei Huang, Pei-Teh Chang, Rahul Subhash Talekar
-
Patent number: 9155739Abstract: Histone deacetylases inhibitors (HDACIs) and methods for treating cancer in a subject in need thereof are disclosed. The HDACIs comprise a compound of Formula X. or a pharmaceutically acceptable salt thereof. In one embodiment of the invention, R1 is ethyl; R2 is 2-phenylethyl; R3 is hydrogen; R4 is fluoro; R5 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; and R6 is hydrogen, or a salt thereof. In another embodiment of the invention, R1 is ethyl; R2 is 2-phenylethyl; R3 is hydrogen; R4 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; R5 is chloro or fluoro; and R6 is hydrogen.Type: GrantFiled: March 23, 2015Date of Patent: October 13, 2015Assignee: ANNJI PHARMACEUTICAL CO., LTD.Inventors: Ji-Wang Chern, Chao-Wu Yu, Pei-Teh Chang
-
Publication number: 20150196563Abstract: Histone deacetylases inhibitors (HDACIs) and methods for treating cancer in a subject in need thereof are disclosed. The HDACIs comprise a compound of Formula X. or a pharmaceutically acceptable salt thereof. In one embodiment of the invention, R1 is ethyl; R2 is 2-phenylethyl; R3 is hydrogen; R4 is fluoro; R5 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; and R6 is hydrogen, or a salt thereof. In another embodiment of the invention, R1 is ethyl: R2 is 2-phenylethyl; R3 is hydrogen; R4 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; R5 is chloro or fluoro: and R6 is hydrogen.Type: ApplicationFiled: March 23, 2015Publication date: July 16, 2015Inventors: Ji-Wang Chern, Chao-Wu Yu, Pei-Teh Chang
-
Patent number: 8969361Abstract: Cyclopropanecarboxylate esters of purine analogues, method of making and using the same for treating herpes virus infections and tumors are disclosed.Type: GrantFiled: April 2, 2013Date of Patent: March 3, 2015Assignee: Annji Pharmaceutical Co., Ltd.Inventors: Ji-Wang Chern, Shin-Yu Lai, Pei-Teh Chang
-
Patent number: 8946282Abstract: A novel class of indoline-2-one derivatives are disclosed. These compounds are protein kinase inhibitors which are useful for treating hyperproliferative diseases such as cancer.Type: GrantFiled: April 3, 2013Date of Patent: February 3, 2015Assignee: Annji Pharmaceutical Co., Ltd.Inventors: Ji-Wang Chern, Ajit Dhananjay Jagtap, Hsiao-Chun Wang, Grace Shiahuy Chen
-
Publication number: 20140296251Abstract: Novel quinoline derivatives are disclosed. Also disclosed are synthesis and use thereof for treating neurodegenerative diseases.Type: ApplicationFiled: April 2, 2013Publication date: October 2, 2014Applicant: Annji Pharmaceutical Co., Ltd.Inventors: Ji-Wang Chern, Chen-Wei Huang, Pei-Teh Chang, Rahul Subhash Talekar
-
Publication number: 20130281517Abstract: Cyclopropanecarboxylate esters of purine analogues, method of making and using the same for treating herpes virus infections and tumors are disclosed.Type: ApplicationFiled: April 2, 2013Publication date: October 24, 2013Inventors: Ji-Wang CHERN, Shin-yu LAI, Pei-Teh CHANG
-
Publication number: 20130281451Abstract: A novel class of indoline-2-one derivatives are disclosed. These compounds are protein kinase inhibitors which are useful for treating hyperproliferative diseases such as cancer.Type: ApplicationFiled: April 3, 2013Publication date: October 24, 2013Applicant: ANNJI PHARMACEUTICAL CO., LTD.Inventors: Ji-Wang Chern, Ajit Dhananjay Jagtap, Hsiao-Chun Wang, Grace Shiahuy Chen
-
Publication number: 20130267542Abstract: Histone deacetylases inhibitors (HDACIs) and compositions comprising the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit are also disclosed.Type: ApplicationFiled: April 2, 2013Publication date: October 10, 2013Applicant: Annji Pharmaceutical Co., Ltd.Inventors: Ji-Wang CHERN, Chao-Wu YU, Pei-Teh CHANG
-
Patent number: 8173693Abstract: The present invention is related to derivatives of benzenesulfonamide represented by formula (I), and the pharmaceutical composition thereof. In addition, the benzenesulfonamide derivatives disclosed in the present invention can serve as potential cell cycle inhibitors, and thereby these benzenesulfonamide derivatives and the pharmaceutical composition thereof can be antitumor drug candidates, which might aim at cell cycle. Particularly, the benzenesulfonamide derivatives disclosed in the present invention may function as antitumor drugs to treat solid cancers.Type: GrantFiled: February 23, 2011Date of Patent: May 8, 2012Assignee: Purzer Pharmaceutical Co., Ltd.Inventors: Ji-Wang Chern, Grace Shiahuy Chen, Pei-Teh Chang, Kuan-Yu Chen, Meng-Ling Chen, Hsueh-Yun Lee, Chiung Hua Huang, Chun-Tang Chiou
-
Publication number: 20110230651Abstract: The present invention is related to derivatives of benzenesulfonamide represented by formula (I), and the pharmaceutical composition thereof. In addition, the benzenesulfonamide derivatives disclosed in the present invention can serve as potential cell cycle inhibitors, and thereby these benzenesulfonamide derivatives and the pharmaceutical composition thereof can be antitumor drug candidates, which might aim at cell cycle. Particularly, the benzenesulfonamide derivatives disclosed in the present invention may function as antitumor drugs to treat solid cancers.Type: ApplicationFiled: February 23, 2011Publication date: September 22, 2011Applicant: Purzer Pharmaceutical Co., LTD.Inventors: Ji-Wang Chern, Grace Shiahuy Chen, Pei-Teh Chang, Kuan-Yu Chen, Meng-Ling Chen, Hsueh-Yun Lee, Chiung Hua Huang, Chun-Tang Chiou
-
Patent number: 6946470Abstract: A method of treating psychosis in a patient which comprises administering a pharmaceutical composition useful in treating psychosis containing a therapeutically effective amount of 1-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one as an active ingredient.Type: GrantFiled: November 12, 2003Date of Patent: September 20, 2005Assignees: Medical and Pharmaceutical Industry Technology and Development Center, National Science CouncilInventors: Ji-Wang Chern, Feng-Nien Ko
-
Publication number: 20050049266Abstract: A method of treating psychosis in a patient which comprises administering a pharmaceutical composition useful in treating psychosis containing a therapeutically effective amount of 1-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one as an active ingredient.Type: ApplicationFiled: November 12, 2003Publication date: March 3, 2005Applicant: Pharmaceutical Industry Technology and Development CenterInventors: Ji-Wang Chern, Feng-Nien Ko
-
Publication number: 20030134866Abstract: A pharmaceutical composition useful in treating psychosis contains a therapeutically effective amount of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one as an active ingredient.Type: ApplicationFiled: May 13, 2002Publication date: July 17, 2003Applicant: Pharmaceutical Industry Technology and Development CenterInventors: Ji-Wang Chern, Feng-Nien Ko
-
Patent number: 6043367Abstract: The present invention features proactive antitumor compounds of the following formula: ##STR1## wherein R.sup.1 is COOZ; Z being H, alkali metal, alkaline earth metal, an ammonium group which is optionally substituted with one or more alkyl groups, or a carboxyl protecting group; each of R.sup.2, R.sup.3, and R.sup.4, independently, is OH or OR.sup.a ; R.sup.a being a hydroxyl protecting group; X is benzene or pyridine, optionally substituted with R.sup.b ; R.sup.b being H, C.sub.1-5 alkyl, C.sub.1-5 alkoxy, NO.sub.2, F, Cl, Br, SO.sub.3 H, and CN; R.sup.5 is H or OH; and each of n and m, independently, is 0 or 1; or a salt thereof.Type: GrantFiled: September 30, 1998Date of Patent: March 28, 2000Inventors: Steve Roffler, Ji-Wang Chern, Ye-Lin Leu
-
Patent number: 5942546Abstract: A compound of the formula: ##STR1## wherein X is arylene, heteroarylene, fused arylene, fused heteroarylene, or deleted; Y is sulfonyl, --O--, or deleted; R.sub.1 is aryl, heteroaryl, fused aryl, or fused heteroaryl; R.sub.2 is H, lower alkyl, lower alkoxy, halo, nitro, cyano, haloalkyl, hydroxyl, carboxyl, amido, amino, or aminoalkyl; or a salt thereof are disclosed. Also disclosed are a pharmaceutical composition which contains an excipient and an effective amount of a compound of the above formula and a method of treating cancer which involves the administration of an effective amount of such a compound to a patient in need thereof.Type: GrantFiled: November 20, 1997Date of Patent: August 24, 1999Assignee: Development Center for BiotechnologyInventors: Ji-Wang Chern, Yu-Ling Leu, Shan-Shue Wang, Chin-Fen Lee, Shih-Chung Hsu
-
Patent number: 5932584Abstract: This invention relates to novel optically active 3-substituted methyl-5-methylthio-2,3-dihydroimidazo?1,2-c!quinazoline (I) and 3-substituted methyl-2,3-dihydroimidazo?1,2-c!quinazolin-5(6H)-one (II). This invention also relates to the therapeutical use of these novel compounds ##STR1## wherein: R is halogen, hydrogen, methoxy, trifluoromethyl, C.sub.1 -C.sub.4 alkyl, nitro, acetyl, cyano or hydroxy group; or pharmaceutically acceptable salts thereof.Type: GrantFiled: May 6, 1997Date of Patent: August 3, 1999Assignee: National Science CouncilInventors: Ji-Wang Chern, Alexander Gutcait, Hsiu-Wen Liu, Kuang-Chao Wang